Unaudited Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Apr. 30, 2022	Apr. 30, 2021
Revenue:
Total revenues	$ 63,354	$ 48,291
Expenses:
Cost of revenue (excluding depreciation and amortization)	14,386	8,534
Payment processing expense	12,158	9,725
Sales and marketing	40,031	15,012
Research and development	20,635	8,054
General and administrative	20,855	12,671
Depreciation	4,278	3,297
Amortization	1,604	1,651
Total expenses	113,947	58,944
Operating loss	(50,593)	(10,653)
Other (expense) income, net	(31)	66
Interest (expense) income, net	(383)	(238)
Total other expense, net	(414)	(172)
Loss before provision for income taxes	(51,007)	(10,825)
Provision for income taxes	(235)	(149)
Net loss	$ (51,242)	$ (10,974)
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (0.99)	$ (0.24)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (0.99)	$ (0.24)
Weighted-average common shares outstanding - basic (in shares)	51,938,887	45,416,431
Weighted-average common shares outstanding - diluted (in shares)	51,938,887	45,416,431
Subscription and related services
Revenue:
Total revenues	$ 29,101	$ 21,819
Payment processing fees
Revenue:
Total revenues	19,381	16,644
Life sciences
Revenue:
Total revenues	$ 14,872	$ 9,828